Legal Briefs: Rx Data Mining Law Upheld, Angiomax Patent Extended, Accutane Verdict Vacated
Executive Summary
First Circuit upholds Maine law on prescribers' privacy: A Maine statute allowing physicians to choose not to make identifying information about their prescribing available for use in marketing is constitutional, the U.S. Court of Appeals for the First Circuit ruled Aug. 4. IMS Health, Verispan and Source Healthcare Analytics filed suit to block the law claiming its restrictions on use of prescribers' identifying data limited free speech and also regulated transactions outside of Maine in violation of the dormant Commerce Clause. In 2008, the First Circuit upheld a similar New Hampshire law that banned the sale of physician prescribing data (1"The Pink Sheet," Nov. 24, 2008). In the current case, IMS v. Mills, the court said the statute regulates conduct not speech and that it "constitutionally reaches plaintiffs' out-of-state transactions as a necessary incident of Maine's strong interest in protecting opted-in Maine prescribers from unwanted solicitations.
You may also be interested in...
FDA Off-Label Regs Face Cave-In Risk After Supreme Court Data-Mining Ruling
Lawyers have pored over the Supreme Court's decision overturning Vermont's prescriber data mining law to see how it may be applied to other forms of pharmaceutical marketing.
FDA Off-Label Regs Face Cave-In Risk After Supreme Court Data-Mining Ruling
Lawyers have pored over the Supreme Court's decision overturning Vermont's prescriber data mining law to see how it may be applied to other forms of pharmaceutical marketing.
Angiomax Patent Term Extension: Will Second Time Be The Charm?
A judge, interpreting the patent statute "liberally," again orders PTO to find that The Medicine Company met the deadline for filing its application for patent term extension.